Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer.

Scientific reports - 12 Jan 2017

Zhao Dan, Chen Xuejing, Qin Na, Su Dan, Zhou Lijuan, Zhang Quan, Li Xi, Zhang Xinyong, Jin Mulan, Wang Jinghui

Abstract excerpt

Clinical trials have shown that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) did not improve the survival of patients with EGFR-mutated non-small cell lung cancer (NSCLC) because of the high crossover of treatments. Realistically, the role of EGFR-TKIs in NSCLC with mutated EGFR is not well known. We retrospectively analysed data from patients with recurrent or metastatic NSCLC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Staging
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Kaplan-Meier Estimate

Share to Lung Neoplasms

Share to Multivariate Analysis

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 28079142
DOI: 10.1038/srep40374
PMCID: PMC5227705

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer.PMID 28079142Read ↗

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.Semantic proximity Read ↗

The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.Semantic proximity Read ↗

Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.Semantic proximity Read ↗

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIsSemantic proximity Read ↗

Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.Semantic proximity Read ↗

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.Semantic proximity Read ↗

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.Semantic proximity Read ↗

Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.Semantic proximity Read ↗

Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.Semantic proximity Read ↗

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.Semantic proximity Read ↗

The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.